SEARCH

SEARCH BY CITATION

References

  • Anderson, J.E., Appelbaum, F.R., Schoch, G., Gooley, T., Anasetti, C., Bensinger, W.I., Bryant, E., Buckner, C.D., Chauncey, T., Clift, R.A., Deeg, H.J., Doney, K., Flowers, M., Hansen, J.A., Martin, P.J., Matthews, D.C., Nash, R.A., Sanders, J.E., Shulman, H., Sullivan, K.M., Witherspoon, R.P., Storb, R. (1996) Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. Journal of Clinical Oncology, 14, 220 226.
  • Appelbaum, F.R. & Anderson, J. (1998) Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia, 12, S25 S29.
  • Appelbaum, F.R., Clift, R., Radich, J., Anasetti, C., Buckner, C.D. (1995) Bone marrow transplantation for chronic myelogenous leukemia (Review). Seminars in Oncology, 22, 405 411.
  • Bacigalupo, A., Gualandi, F., Van Lint, M.T., Sessarego, M., Frassoni, F., Occhini, D., Lamparelli, T., Oneto, R., Vitale, V., Corvo, R. (1993) Multivariate analysis of risk factors for survival and relapse in chronic granulocytic leukemia following allogeneic marrow transplantation: impact of disease related variables. Bone Marrow Transplantation, 12, 443 448.
  • Bain, B.J. (1999) The relationship between the myelodysplastic syndromes and the myeloproliferative disorders (Review). Leukemia and Lymphoma, 34, 443 449.
  • Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A.G., Gralnick, H.R., Sultan, C. & The French–American–British (FAB) Co-operative Group (1982) Proposals for the classification of the myelodysplastic syndromes. British Journal of Haematology, 51, 189 199.
  • Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A.G., Gralnick, H., Sultan, C., Cox, C. (1994) The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French–American–British Cooperative Leukaemia Group. British Journal of Haematology, 87, 746 754.
  • Beran, M., Kantarjian, H., O'Brien, S., Koller, C., Al-Bitar, M., Arbuck, S., Pierce, S., Moore, M., Abruzzese, J.L., Andreeff, M., Keating, M., Estey, E. (1996) Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood, 88, 2473 2479.
  • Cambier, N., Wattel, E., Menot, M.L., Guerci, A., Chomienne, C., Fenaux, P. (1996) All-trans retinoic acid in adult chronic myelomonocytic leukemia: results of a pilot study. Leukemia, 10, 1164 1167.
  • Cambier, N., Baruchel, A., Schlageter, M.H., Menot, M.L., Wattel, E., Fenaux, P., Chomienne, C. (1997) Chronic myelomonocytic leukemia: from biology to therapy (Review). Hematology and Cell Therapy, 39, 41 48.
  • Cheson, B.D., Jasperse, D.M., Simon, R., Friedman, M.A. (1986) A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. Journal of Clinical Oncology, 4, 1857 1864.
  • Cox, D.R. (1972) Regression models and life-tables (with discussions), Series B. Journal of the Royal Statistical Society, 34, 187 220.
  • Deeg, H.J., Lin, D., Leisenring, W., Boeckh, M., Anasetti, C., Appelbaum, F.R., Chauncey, T.R., Doney, K., Flowers, M., Martin, P., Nash, R., Schoch, G., Sullivan, K.M., Witherspoon, R.P., Storb, R. (1997) Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. Blood, 89, 3880 3887.
  • Fenaux, P., Jouet, J.P., Zandecki, M., Lai, J.L., Simon, M., Pollet, J.P., Bauters, F. (1987) Chronic and subacute myelomonocytic leukaemia in the adult: a report of 60 cases with special reference to prognostic factors. British Journal of Haematology, 65, 101 106.
  • Fenaux, P., Beuscart, R., Lai, J.L., Jouet, J.P., Bauters, F. (1988) Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases. Journal of Clinical Oncology, 6, 1417 1424.
  • Fenaux, P., Morel, P., Rose, C., Lai, J.L., Jouet, J.P., Bauters, F. (1991) Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. British Journal of Haematology, 77, 497 501.
  • Goldman, J.M., Szydlo, R., Horowitz, M.M., Gale, R.P., Ash, R.C., Atkinson, K., Dicke, K.A., Gluckman, E., Herzig, R.H., Marmont, A., Masaoka, T., McGlave, P.B., Messner, H., O'Reilly, R.J., Reiffers, J., Rimm, A.A., Speck, B., Veum-Stone, J.A., Wingard, J.R., Zwaan, F.E., Bortin, M.M. (1993) Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood, 82, 2235 2238.
  • Gratwohl, A., Hermans, J., Niederwieser, D., Frassoni, F., Arcese, W., Gahrton, G., Bandini, G., Carreras, E., Vernant, J.P., Bosi, A. (1993) Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic leukemia working party of the European group for bone marrow transplantation. Bone Marrow Transplantation, 12, 509 516.
  • Greenberg, P., Cox, C., LeBeau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G., Bennett, J. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, 2079 2088.
  • Kalbfleisch, J.D. & Prentice, R.L. (1980) The Statistical Analysis of Failure Time Data. John Wiley & Sons, New York.
  • Kaplan, E.L. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457 481.
  • Michaux, J.L. & Martiat, P. (1993) Chronic myelomonocytic leukaemia (CMML) – a myelodysplastic or myeloproliferative syndrome? (Review). Leukemia and Lymphoma, 9, 35 41.
  • Nash, R.A., Pineiro, L.A., Storb, R., Deeg, H.J., Fitzsimmons, W.E., Furlong, T., Hansen, J.A., Gooley, T., Maher, R.M., Martin, P., McSweeney, P.A., Sullivan, K.M., Anasetti, C., Fay, J.W. (1996) FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. Blood, 88, 3634 3641.
  • Petersdorf, E.W., Gooley, T.A., Anasetti, C., Martin, P.J., Smith, A.G., Mickelson, E.M., Woolfrey, A.E., Hansen, J.A. (1998) Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood, 92, 3515 3520.
  • Storb, R., Deeg, H.J., Whitehead, J., Appelbaum, F., Beatty, P., Bensinger, W., Buckner, C.D., Clift, R., Doney, K., Farewell, V., Hansen, J., Hill, R., Lum, L., Martin, P., McGuffin, R., Sanders, J., Stewart, P., Sullivan, K., Witherspoon, R., Yee, G., Thomas, E.D. (1986) Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. New England Journal of Medicine, 314, 729 735.
  • Tefferi, A., Hoagland, H.C., Therneau, T.M., Pierre, R.V. (1989) Chronic myelomonocytic leukemia: natural history and prognostic determinants. Mayo Clinic Proceedings, 64, 1246 1254.
  • Thomas, E.D. & Clift, R.A. (1999) Allogeneic transplantation for chronic myeloid leukemia. In: Hematopoietic Cell Transplantation, 2nd edn (ed. by E.D.Thomas, K.G.Blume & S.J.Forman), p. 807. Blackwell Science, Boston.
  • Vallespi, T., Imbert, M., Mecucci, C., Preudhomme, C., Fenaux, P. (1998) Diagnosis, classification, and cytogenetics of myelodysplastic syndromes (Review). Haematologica, 83, 258 275.
  • Wattel, E., Guerci, A., Hecquet, B., Economopoulos, T., Copplestone, A., Mahe, B., Couteaux, M.E., Resegotti, L., Voglova, V., Foussard, C., Pegourie, B., Michaux, J.L., Deconinck, E., Stoppa, A.M., Mufti, G., Oscier, D., Fenaux, P., Groupe francais des Myelodysplasies & European CMML Group (1996) A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Blood, 88, 2480 2487.
  • Worsley, A., Oscier, D.G., Stevens, J., Darlow, S., Figes, A., Mufti, G.J., Hamblin, T.J. (1988) Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival. British Journal of Haematology, 68, 17 21.